Whalesbook
Teji se badhta GLP-1 Market Ab Sasta Hoga?
Health Canada ka ye approval Dr. Reddy's ke liye ek bada game-changer hai. Ab jo ye mahangi GLP-1 therapies hain, jo pehle sirf bade pharma companies bana rahi thi, woh ab sabke liye accessible ho jayengi aur prices kam honge.
Dr. Reddy's ne sabse pehla generic semaglutide approval pa liya hai, jo Novo Nordisk ke Ozempic aur Wegovy drugs mein use hota hai. Aur jab generic drugs aate hain, toh prices 45% se lekar 90% tak kam ho sakte hain. Socho, ek mahine ka treatment globally shayad sirf $14 mein mil paaye!
Ye jo GLP-1 market hai na, ye bahut bada hai, $53.46 billion ka 2024 mein aur $156.71 billion tak jaane ki ummeed hai 2030 tak. Ab tak iska 80% hissa Novo Nordisk aur Eli Lilly ke paas hai. Lekin ab jab generic aa gaye, toh competition toh badhega hi. Novo Nordisk khud keh raha hai ki 2026 mein unka revenue 5% se 13% tak gir sakta hai U.S. pricing pressure aur competition ki wajah se. Stock bhi unka 75% gir chuka hai apne high se.
Dr. Reddy's ki market value $11.3 billion hai, toh unko fayda hoga, par unko bhi competition face karna padega kyunki Health Canada mein aur 8 se zyada generic applications pending hain. Analysts ke views mixed hain. Citi jaise log ise 'Sell' rating de rahe hain, kyunki unka kehna hai ki Canadian generics se Dr. Reddy's ko 2028 tak sirf $50 million revenue milega, jabki 5 aur companies compete karengi.
Overall, ye sirf Canada mein shuruat hai, poori duniya mein GLP-1 drugs ke liye business model change hone wala hai. Is generic shift se drugmakers ke profits par bada impact padega. Eli Lilly ka tirzepatide (Mounjaro) aur naye oral drugs bhi competition badha rahe hain. Companies ko ab naye strategies sochne padenge.